挪威原发转移性前列腺癌患者在新抗肿瘤药物引入前后的生存趋势
该研究基于挪威癌症登记处5542例原发转移性前列腺癌(mPCa)患者,按新药引入前后分三个诊断时期(2004-2009、2010-2014、2015-2018)分析生存。结果显示中位总生存(OS)从2.3年增至3.3年,3年OS从41%升至51%,校正已知预后因素后生存改善仍持续,可能与新药引入相关。
要点
- 挪威mPCa患者中位OS从2004-2009年的2.3年增至2015-2018年的3.3年。
- 3年OS从41%提高至51%,校正预后因素后改善仍显著。
- 更早诊断期、更高T分期、更高ISUP分级、更低WHO状态及更高PSA与更差CSS相关。
核心结论
- 挪威mPCa患者自2004年以来中位OS增加1年,生存改善在校正已知预后因素后持续存在,可能与新药引入相关。
研究设计与样本
- 基于挪威癌症登记处的回顾性队列研究,纳入5542例原发mPCa患者,诊断于2004-2018年。
- 另分析2738例可能符合新药治疗条件的亚组(年龄<80岁、WHO体能状态≤2且诊断后3个月内未死亡)。
- 按新药引入挪威的时间分为三个诊断时期:2004-2009年(引入前)、2010-2014年(中间期)、2015-2018年(引入后)。
- 采用Kaplan-Meier生存分析和多变量Cox回归估计总生存(OS)和病因特异性生存(CSS)。
主要发现
- 中位OS从2004-2009年的2.3年增加至2015-2018年的3.3年。
- 3年OS从2004-2009年的41%提高至2015-2018年的51%。
- 更早诊断期、更高T分期、更高ISUP分级分组、更低WHO体能状态和更高PSA水平与更低的CSS相关。
- 亚组分析结果与总体人群相似。
临床怎么用
- 提示新药引入后mPCa患者人群水平生存改善,支持在符合条件的患者中应用新型抗肿瘤药物。
- 评估预后时应考虑诊断时期、T分期、ISUP分级、WHO体能状态和PSA水平等预后因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: During the past two decades, new antitumor drugs (Abiraterone, Enzalutamide, Radium-223, Cabazitaxel, and Docetaxel) have been introduced for treatment of prostate cancer with distant metastases (mPCa). Each drug have demonstrated a survival gain in studies, but little is known about the impact in a general population of mPCa patients. In this study we assessed survival before and after introduction of the new drugs for Norwegian mPCa patients. METHODS: Survival was assessed in 5542 patients with primary mPCa. The patients were diagnosed between 2004 and 2018, identified in the Norwegian Cancer Registry. We also analyzed a subgroup of 2738 patients possibly eligible for treatment with new drugs (age <80 years, WHO performance status ≤2 and not dead within 3 months from diagnosis). We estimated overall (OS) and cause-specific survival (CSS) across three diagnostic time periods reflecting to the drugs' introduction in Norway: Before (2004-2009), "in between" (2010-2014) and after the introduction (2015-2018). We used Kaplan-Meier survival analysis and multivariable Cox regression. RESULTS: Median OS increased from 2.3 years in 2004-2009 to 3.3 years in 2015-2018. 3-year OS improved from 41% in 2004-2009 to 51% in 2015-2018. An earlier diagnostic period, a more advanced T stage, higher ISUP grade group, lower WHO status and higher PSA levels were associated with a lower CSS. Similar results was found for the subgroup. CONCLUSIONS: Median OS of mPCa has increased by one year since 2004 for mPCa patients in Norway. Survival improvement persisted after adjustment for recognized prognostic factors and may be related to the introduction of new drugs in Norway.
引用
- Storås AH, Fosså SD, Ursin G, et al. Survival trends for patients with primary metastatic prostate cancer before and after the introduction of new antitumor drugs. Prostate Cancer Prostatic Dis. 2021. PMID: 34493838. doi:10.1038/s41391-021-00445-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。